NASHVILLE, Tenn., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, announced results for the second quarter ...
MELT-300 and MELT-210 Programs on Track for New Drug Application Filings Harrow’s ImprimisRx Settles Pending Regulatory Matters with the California Board of Pharmacy Mark L. Baum, Chief Executive ...
Harrow Health, Inc. (NASDAQ:HROW) Q3 2025 Earnings Call Transcript November 11, 2025 Operator: Good day, and welcome to the Harrow Third Quarter 2025 Earnings Conference Call. [Operator Instructions] ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results